GeoVax Labs has recruited Dr. Senthil Ranganathan as Vice President of Technical Development and CMC Operations, a strategic move that underscores the company's commitment to advancing its clinical-stage vaccine and immunotherapy portfolio. With over two decades of experience in biologics development, Dr. Ranganathan brings critical expertise in transitioning scientific innovations from research to commercial readiness.
The appointment comes at a crucial stage for GeoVax, which is developing vaccines for infectious diseases and cancer therapies. Dr. Ranganathan's background includes leadership roles in process development and manufacturing operations at prominent biopharmaceutical companies, positioning him to support the company's goals of addressing unmet medical needs and enhancing biodefense capabilities.
Dr. Ranganathan's previous experience spans a wide range of biologics, including cell and gene therapies, vaccines, and monoclonal antibodies. His expertise will be particularly valuable as GeoVax advances its key clinical programs, including a next-generation COVID-19 vaccine and an oncolytic solid tumor gene-directed therapy.
GeoVax CEO David Dodd highlighted the strategic importance of the appointment, emphasizing Dr. Ranganathan's potential to support the company's progression towards authorization and commercialization of its development portfolio. The addition of such an experienced executive signals GeoVax's serious intent to bring innovative medical solutions to market.
